51. 全身性強皮症 [臨床試験数:466,薬物数:536(DrugBank:142),標的遺伝子数:110,標的パスウェイ数:210

Searched query = "Scleroderma", "Systemic sclerosis", "SSc", "dcSSc", "lcSSc"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
10 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04040322October 14, 201930/7/2019Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)Raynaud's Phenomenon Secondary to Systemic SclerosisDrug: Placebo IV infusion;Drug: Iloprost Injection, for intravenous useEicos Sciences, Inc.NULLRecruiting18 YearsN/AAll180Phase 3United States
2NCT03867097March 4, 20196/3/2019Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic SclerosisRaynaud Phenomenon Secondary to Systemic SclerosisDrug: Placebo IV infusion;Drug: Iloprost Injection, for intravenous useEicos Sciences, Inc.NULLCompleted18 YearsN/AAll41Phase 2United States
3EUCTR2016-002984-32-IT16/02/201705/02/2018NDTreatment of the Reynaud's Disease associated with ischemic ulcers in patients affected by sistemic sclerosis - ND SISTEMIC SCLEROSIS
MedDRA version: 20.0Level: LLTClassification code 10042953Term: Systemic sclerosisSystem Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]
Trade Name: ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA
Product Name: ENDOPROST
INN or Proposed INN: ILOPROST TROMETAMOL
Other descriptive name: ILOPROST SALE DI TROMETAMOLO
Trade Name: ENDOPROST - 0.05 MG/0.5 ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FIALA
Product Name: ENDOPROST
Product Code: ND
INN or Proposed INN: ILOPROST TROMETAMOL
Other descriptive name: ILOPROST SALE DI TROMETAMOLO
UNIVERSITÀ CATTOLICA DEL SACRO CUORE- POLICLINICO A. GEMELLINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
238Phase 4Italy
4EUCTR2013-004596-12-IT22/01/201413/12/2013Infusion at home ,using a pump device, of a drug that dilates peripheral blood vessels to treat patients affected by a disease named Systemic sclerosis, with manifestations caused by a reduced blood flow in hands and feet.HOME INFUSION THERAPY WITH ILOPROST USING A PORTABLE SYRINGE PUMP FOR THE TREATMENT OF PERIPHERAL ULCERS AND RAYNAUD'S PHENOMENON IN SYSTEMIC SCLEROSIS. - iloporta Raynaud's phenomenon and acral ulcers in systemic sclerosis;Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]Trade Name: Endoprost
Product Name: Endoprost
Azienda ospedaliera universitaria Ospedali RiunitiNULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
20Phase 2Italy
5NCT00428883January 200729/1/2007High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic SclerosisRare Disease With Microvascular Involvement: High Dose Intravenous N-Acetylcysteine Versus Iloprost for Early, Rapidly Progressive Diffuse Systemic SclerosisScleroderma, DiffuseDrug: N-acetylcysteine (NAC)Università Politecnica delle MarcheNULLRecruiting18 Years80 YearsBoth45Phase 2/Phase 3Italy
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6EUCTR2006-003957-25-IT13/10/200609/07/2007Rare Diseases with microvascular involvement. High Dose Intravenous N-acetylcysteine versus Iloprost for early, rapidlyprogressive diffuse Systemic Sclerosis (Scleroderma) - N-Acetylcisteine vs Iloprost in SScRare Diseases with microvascular involvement. High Dose Intravenous N-acetylcysteine versus Iloprost for early, rapidlyprogressive diffuse Systemic Sclerosis (Scleroderma) - N-Acetylcisteine vs Iloprost in SSc Systemic Scleroderma
MedDRA version: 9.1Level: LLTClassification code 10055953Term: Scleroedema
Trade Name: HIDONAC*EV 1FL 5G 25ML
INN or Proposed INN: Acetylcysteine
Trade Name: ENDOPROST 50*INFUS 1F 0,050MG/
INN or Proposed INN: Iloprost
AZIENDA OSPEDALIERO UNIVERSITARIA OSPEDALI RIUNITI UMBERTO I - G.M.LANCISI - G.SALESINULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
Italy
7EUCTR2006-000905-41-AT07/06/200608/05/2006Offene, monozentrische, randomisierte, placebo-kontrollierte, einfach blinde und Observer-blinde klinische Studie bei PatientInnen mit Raynaud Syndrom mit / ohne progressiver systemischer Sklerodermie zur systemischen Therapie mit Iloprost versus Placebo - iloprost in raynaudOffene, monozentrische, randomisierte, placebo-kontrollierte, einfach blinde und Observer-blinde klinische Studie bei PatientInnen mit Raynaud Syndrom mit / ohne progressiver systemischer Sklerodermie zur systemischen Therapie mit Iloprost versus Placebo - iloprost in raynaud Raynaud syndrome with / without systemic sclerosisTrade Name: Ilomedin
Product Name: Ilomedin
Product Code: 1-22460
ao. Univ. Prof. Dr. Elisabeth AbererNULLNot RecruitingFemale: yes
Male: yes
Phase 4Austria
8EUCTR2004-002712-28-IT28/02/200515/02/2006Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study.Chronic iloprost administration in scleroderma patients effect on disease progression, as assessed by skin fibrosis evaluation. A randomized, controlled, blind-observer, multicenter phase III study. Disease progression in scleroderma.
MedDRA version: 6.1Level: HLTClassification code 10039711
Trade Name: ENDOPROST 0,05MG/0,5ML 1F
INN or Proposed INN: iloprost trometamol
ITALFARMACONULLNot RecruitingFemale: yes
Male: yes
69Phase 3Italy
9NCT00622687September 199714/2/2008Effect of Different Iloprost Doses on Symptoms in Systemic SclerosisComparision Between Maximally Tolerated Intravenous Iloprost Doses Versus Low-Dosed Iloprost for a 21-Day Treatment CourseSystemic SclerosisDrug: iloprost;Drug: iloprost low dose;Drug: iloprost therapy up to 2 ng/kg x minCharite University, Berlin, GermanySchering-PloughTerminated18 Years80 YearsBoth50Phase 2Germany
10NCT00004786December 199524/2/2000Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic SclerosisSystemic Sclerosis;Raynaud DiseaseDrug: iloprostNational Center for Research Resources (NCRR)University of PittsburghCompleted18 YearsN/ABoth200Phase 3NULL